https://sputnikglobe.com/20210301/rdif-received-many-requests-from-eu-states-for-direct-supplies-of-sputnik-v-ceo-says-1082221999.html
RDIF Received Many Requests From EU States for Direct Supplies of Sputnik V, CEO Says
RDIF Received Many Requests From EU States for Direct Supplies of Sputnik V, CEO Says
Sputnik International
MOSCOW (Sputnik) - The Russian Direct Investment Fund (RDIF) has received many requests from EU countries for direct supplies of coronavirus vaccine Sputnik V... 01.03.2021, Sputnik International
2021-03-01T18:32+0000
2021-03-01T18:32+0000
2023-04-12T17:13+0000
https://cdn1.img.sputnikglobe.com/img/07e5/02/10/1082087607_0:292:3077:2031_1920x0_80_0_0_525531198ab94575f049809b28c46121.jpg
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
2021
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
News
en_EN
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
Sputnik International
feedback@sputniknews.com
+74956456601
MIA „Rossiya Segodnya“
newsfeed, vaccine, russian direct investment fund (rdif), european union (eu)
newsfeed, vaccine, russian direct investment fund (rdif), european union (eu)
RDIF Received Many Requests From EU States for Direct Supplies of Sputnik V, CEO Says
18:32 GMT 01.03.2021 (Updated: 17:13 GMT 12.04.2023) MOSCOW (Sputnik) - The Russian Direct Investment Fund (RDIF) has received many requests from EU countries for direct supplies of coronavirus vaccine Sputnik V, and will continue to work in this direction and cooperate with the European Medicines Agency (EMA), the fund's CEO, Kirill Dmitriev, said.
"We have received numerous requests from EU states to provide Sputnik V directly to them based on the reviews of their national agencies. We will continue to do so as well as work with EMA based on the rolling review procedure we initiated in January", Dmitriev said, as quoted by the fund's press service.
The Russian vaccine, developed by the Gamaleya Epidemiology and Microbiology Centre and registered by the Russian Ministry of Health on 11 August, was the world's first registered vaccine against the coronavirus.
In February, peer-reviewed medical journal The Lancet published an interim analysis from Phase III clinical trial of the Russian vaccine, showing its 91.6-percent efficacy against symptomatic COVID-19.
